Abstract Background Meningiomas lack effective therapies for recurrent or aggressive disease. NF2 inactivation, commonly in meningioma, may sensitize tumors to FAK inhibition and interact with MAPK signaling. This study investigated the therapeutic activity of defactinib (FAK inhibitor) and avutometinib (RAF/MEK inhibitor) alone and in combination in preclinical meningioma models. Methods MAPK-altered meningioma cell lines, IOMM-Lee (NF2 wild-type, BRAF p.V600E) and CH157-MN (NF2 mutant, NRAS p.Q61K), BenMen-1 (NF2 mutant, MAPK wild-type), and three patient-derived NF2 mutant cell lines were cultured in matrigel and treated with defactinib and avutometinib in 3D cell viability assays. In vivo, flank and intracranial xenograft models of IOMM-Lee and CH157-MN were treated with VS-4718 (FAK inhibitor, superior pharmokinetics in mice), avutometinib, or combination. Tumor growth, survival, and pharmacokinetic/pharmacodynamic properties were assessed. Results In vitro, combination therapy showed synergistic or additive effects in CH157-MN and IOMM-Lee cells, respectively. Defactinib alone demonstrated activity in NF2-mutant patient-derived and BenMen-1 cells, while avutometinib did not. In vivo, avutometinib monotherapy suppressed tumor growth and extended survival in both flank and intracranial xenograft models, with evidence of favorable pharmacokinetic properties and target pathway inhibition in intracranial tumors. Combination therapy provided enhanced and sustained control of flank CH157-MN meningioma compared to avutometinib alone but did not significantly improve survival over avutometinib alone in intracranial models. Conclusions Avutometinib demonstrated robust anti-tumor effects in flank and intracranial models of MAPK-altered meningioma. Combination benefits were context dependent. Defactinib activity in NF2-mutant patient-derived cells without targetable MAPK-kinase alterations highlights the importance of genomic biomarkers to guide personalized strategies.
DDDR-71. Dual inhibition of RAF/MEK and FAK signaling improves survival in intracranial meningioma models
Abstract BACKGROUND High-grade and recurrent meningiomas frequently demonstrate aggressive behavior and therapeutic resistance, with limited treatment options. Dysregulation of the MAPK and FAK pathways drive meningioma progression, but compensatory activation between these pathways could limit single agent efficacy. Recently, a clinical trial (Alliance A071401) showed encouraging efficacy of single-agent FAK inhibition in recurrent/progressive meningioma (Brastianos et al, JCO 2023). This preclinical study aimed to evaluate the therapeutic potential of dual RAF/MEK (avutometinib) and FAK (VS-4718) inhibition in suppressing tumor growth and improving survival in intracranial meningioma models. METHODS Orthotopic intracranial models were established by injecting IOMM-Lee (Fluc-mCherry) or CH157-MN (eGFP-LUC2) cells into nu/nu mice. Mice were randomized into four groups: vehicle, VS-4718 (murine formulation of defactinib, 50 mg/kg, BID), avutometinib (0.3 mg/kg, QD), or combination therapy. Treatments were administered for a 4-week period. Tumor growth was monitored via bioluminescent imaging (BLI) at baseline, midpoint, and study endpoint. Pharmacokinetic (PK) and pharmacodynamic (PD) effects were assessed by intratumoral drug concentrations and Western blotting for p-ERK and p-AKT, respectively. RESULTS In the NF2-mutant CH157-MN model, avutometinib increased median survival from 12.5 to 20.5 days (p=0.001), while combination therapy extended survival further to 22 days (p<0.0001 vs vehicle). Similarly, in the NF2-wildtype IOMM-Lee model, avutometinib raised survival from 27.5 to 33 days (p=0.0237), with combination therapy reaching 34.5 days (p=0.0057 vs vehicle). VS-4718 monotherapy did not extend survival in both models. BLI demonstrated significant inhibition of tumor growth in both avutometinib and combination groups in both tumor models. PK analysis revealed Kp values of 0.26–0.37 for avutometinib and 0.46–0.50 for VS-4718 in orthotopic tumor tissue. Furthermore, combination therapy lowered p-ERK in tumors (p=0.001) compared to vehicle. CONCLUSION Dual RAF/MEK and FAK inhibitor therapy blocks MAPK activation and enhances survival in orthotopic meningioma models, supporting further clinical evaluation for aggressive meningiomas.
Impact on urinary oxalate levels with use of ezetimibe
AbstractBackgroundCalcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of <15 patients investigating ezetimibe, a selective cholesterol absorption inhibitor, have suggested increased urine oxalate levels with use of the drug. We attempt to better define this relationship of ezetimibe on urinary oxalate using a larger patient sample analysing multiple urine collections on and off treatment.Materials and MethodsWe retrospectively reviewed all consecutive patients from 01/2018 through 04/2019 evaluated for nephrolithiasis with use of ezetimibe documented in their medical record at Mayo Clinic Florida. Primary outcomes included increase in urinary oxalate with use of ezetimibe and reduction in urinary oxalate with discontinuation of medication.ResultsOf 57 reviewed patients, 30 (53%) met inclusion criteria yielding 117 24‐h urine measurements either on ezetimibe (72 measurements) or off ezetimibe (41 measurements). The mean urinary oxalate level off ezetimibe was 39.86 mg versus 40.45 mg with ezetimibe. After adjusting for age and sex, the estimated difference was 1.239 mg (95% CI, −4.856 to 7.335 mg; p = 0.93). A subset of six patients with urinary oxalate values both on and off ezetimibe showed a difference in 24‐h urinary oxalate levels ranged from −16.40 to 14.95 mg (mean difference = 0.93 mg; median difference = 3.84 mg).ConclusionUse of ezetimibe does not provide clear evidence of a difference in urinary oxalate levels.